Business Context and Reporting Period
This Form 8-K, filed on May 12, 2022, reports events occurring on May 7 and May 9, 2022, for Cortexyme, Inc. (CRTX). The filing details the entry into a definitive merger agreement with Novosteo Inc., a privately held biotechnology company focused on rare skeletal diseases and bone cancer. The transaction involves a two-step merger where Novosteo will become a wholly-owned subsidiary of Cortexyme.
Key Financial Metrics and Liquidity
The filing does not provide historical revenue, profit, or cash flow data for Cortexyme or Novosteo. Key financial disclosures include:
- Pro Forma Liquidity: Upon completion of the merger, the combined entity expects to have approximately $120 million in cash, cash equivalents, and investments as of March 31, 2022. This figure is preliminary and unaudited.
- Equity Issuance: Cortexyme will issue approximately 6 million shares of common stock (including shares subject to assumed equity awards) to Novosteo stockholders. Non-accredited investors will receive cash in lieu of shares.
- Novosteo Financial Status: Novosteo has not yet generated revenues.
Material Changes and Transaction Terms
The primary material change is the execution of the Merger Agreement. Key terms include:
- Exchange Ratio: The number of Cortexyme shares to be issued for each Novosteo share will be determined at closing.
- Timeline: Closing is anticipated within 30 days of signing (by June 8, 2022), subject to customary conditions including Novosteo stockholder approval.
- Leadership Transition: Upon closing, Dirk Thye, M.D. (current Novosteo CEO) will become Cortexyme's CEO. Karen Smith, M.D., Ph.D. will become Chief Medical Officer, and Brendan Hannah will become Chief Business Officer.
- Board Expansion: The Board will expand to include Dr. Thye and Philip Low, Ph.D. (current Novosteo directors).
Executive Compensation and Equity Plans
The Board approved a 2022 Inducement Plan reserving 4,000,000 shares for new hires. Specific arrangements for Dr. Thye include:
- Base Salary: $550,000 annually.
- Bonus: Up to 50% of base salary.
- Equity: An option grant to ensure 5% ownership of fully diluted capitalization post-merger, vesting over four years.
- Severance: Includes 12 months of salary and 50% equity acceleration for termination without cause; 18 months of salary and 100% equity acceleration in connection with a change in control.
Outlook, Risks, and Contingencies
Outlook: Novosteo's lead candidate, NOV004, is expected to enter Phase 1 clinical trials in 2023 for osteogenesis imperfecta, fractures, and spinal fusion. The merger aims to combine Cortexyme's resources with Novosteo's drug-targeting platform.
Risks and Contingencies:
- Closing Conditions: The transaction is subject to stockholder approval, accuracy of representations, and absence of legal prohibitions.
- Termination Rights: The agreement includes a termination right if the merger is not consummated by June 8, 2022.
- Forward-Looking Statements: The company warns that actual results may differ materially due to risks described in their Form 10-Q, including clinical trial outcomes and regulatory approvals.
Investor Verification Checklist
- Verify the final Exchange Ratio and total share count to be issued upon closing.
- Confirm the outcome of the Novosteo stockholder vote required for the merger.
- Review the unaudited pro forma financial data ($120 million liquidity) against Cortexyme's latest audited 10-Q.
- Monitor the June 8, 2022 deadline for the consummation of the merger.
- Assess the clinical timeline and regulatory pathway for Novosteo's lead candidate, NOV004.